NCT05397405 Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
| NCT ID | NCT05397405 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Condition | Intracranial Artery Stenosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2022-05-23 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2022-05-23 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years 2. Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment 3. low density lipoprotein cholesterol \> 70mg/dl (1.8mmol/L) 4. Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained. 5. Lipid-lowering indications of statins 6. Signed an approved informed consents Exclusion Criteria: 1. Contraindications to statins 2. There are contraindications to MRI examination or cannot accept MRI examination 3. Stenosis caused by vasculitis, arterial dissection and moyamoya disease 4. Patients with active bleeding or obvious bleeding tendency 5. Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating 6. Uncontrolled severe diabetes and hypertension 7. Other conditions inappropriate for inclusion judged by investigators
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05397405 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Intracranial Artery Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05397405 currently recruiting?
Yes, NCT05397405 is actively recruiting participants. Contact the research team at zhjsh333@126.com for enrollment information.
Where is the NCT05397405 trial being conducted?
This trial is being conducted at Nanjing, China, Nanjing, China.
Who is sponsoring the NCT05397405 clinical trial?
NCT05397405 is sponsored by Nanjing First Hospital, Nanjing Medical University. The trial plans to enroll 180 participants.